These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38307935)

  • 1. A novel exosome based therapeutic intervention against neuroendocrine prostate cancer.
    Saini S; Sreekumar A; Nathani S; Asante DM; Simmons MN
    Sci Rep; 2024 Feb; 14(1):2816. PubMed ID: 38307935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer.
    DeLucia DC; Cardillo TM; Ang L; Labrecque MP; Zhang A; Hopkins JE; De Sarkar N; Coleman I; da Costa RMG; Corey E; True LD; Haffner MC; Schweizer MT; Morrissey C; Nelson PS; Lee JK
    Clin Cancer Res; 2021 Feb; 27(3):759-774. PubMed ID: 33199493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A highly-specific fully-human antibody and CAR-T cells targeting CD66e/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo.
    Baek DS; Kim YJ; Vergara S; Conard A; Adams C; Calero G; Ishima R; Mellors JW; Dimitrov DS
    Cancer Lett; 2022 Jan; 525():97-107. PubMed ID: 34740610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting RET Kinase in Neuroendocrine Prostate Cancer.
    VanDeusen HR; Ramroop JR; Morel KL; Bae SY; Sheahan AV; Sychev Z; Lau NA; Cheng LC; Tan VM; Li Z; Petersen A; Lee JK; Park JW; Yang R; Hwang JH; Coleman I; Witte ON; Morrissey C; Corey E; Nelson PS; Ellis L; Drake JM
    Mol Cancer Res; 2020 Aug; 18(8):1176-1188. PubMed ID: 32461304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.
    Bishop JL; Thaper D; Vahid S; Davies A; Ketola K; Kuruma H; Jama R; Nip KM; Angeles A; Johnson F; Wyatt AW; Fazli L; Gleave ME; Lin D; Rubin MA; Collins CC; Wang Y; Beltran H; Zoubeidi A
    Cancer Discov; 2017 Jan; 7(1):54-71. PubMed ID: 27784708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer.
    Van Emmenis L; Ku SY; Gayvert K; Branch JR; Brady NJ; Basu S; Russell M; Cyrta J; Vosoughi A; Sailer V; Alnajar H; Dardenne E; Koumis E; Puca L; Robinson BD; Feldkamp MD; Winkis A; Majewski N; Rupnow B; Gottardis MM; Elemento O; Rubin MA; Beltran H; Rickman DS
    Cancer Res Commun; 2023 Aug; 3(8):1447-1459. PubMed ID: 37546702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment and characterization of a novel treatment-related neuroendocrine prostate cancer cell line KUCaP13.
    Okasho K; Mizuno K; Fukui T; Lin YY; Kamiyama Y; Sunada T; Li X; Kimura H; Sumiyoshi T; Goto T; Kobayashi T; Lin D; Wang Y; Collins CC; Inoue T; Ogawa O; Akamatsu S
    Cancer Sci; 2021 Jul; 112(7):2781-2791. PubMed ID: 33960594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer.
    Imberti C; De Gregorio R; Korsen JA; Hoang TT; Khitrov S; Kalidindi T; Nandakumar S; Park J; Zaidi S; Pillarsetty NVK; Lewis JS
    J Nucl Med; 2024 Jul; 65(7):1043-1050. PubMed ID: 38782457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addressing the need for more therapeutic options in neuroendocrine prostate cancer.
    Kemble J; Kwon ED; Karnes RJ
    Expert Rev Anticancer Ther; 2023 Feb; 23(2):177-185. PubMed ID: 36698089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of MicroRNAs in Neuroendocrine Prostate Cancer.
    Sreekumar A; Saini S
    Noncoding RNA; 2022 Mar; 8(2):. PubMed ID: 35447888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma.
    Sulsenti R; Frossi B; Bongiovanni L; Cancila V; Ostano P; Fischetti I; Enriquez C; Guana F; Chiorino G; Tripodo C; Pucillo CE; Colombo MP; Jachetti E
    Front Immunol; 2021; 12():622001. PubMed ID: 33737929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models.
    Sooreshjani MA; Kamra M; Zoubeidi A; Shah K
    J Biomed Sci; 2021 Oct; 28(1):68. PubMed ID: 34625072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DPYSL5 is highly expressed in treatment-induced neuroendocrine prostate cancer and promotes lineage plasticity via EZH2/PRC2.
    Kaarijärvi R; Kaljunen H; Nappi L; Fazli L; Kung SHY; Hartikainen JM; Paakinaho V; Capra J; Rilla K; Malinen M; Mäkinen PI; Ylä-Herttuala S; Zoubeidi A; Wang Y; Gleave ME; Hiltunen M; Ketola K
    Commun Biol; 2024 Jan; 7(1):108. PubMed ID: 38238517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The central role of Sphingosine kinase 1 in the development of neuroendocrine prostate cancer (NEPC): A new targeted therapy of NEPC.
    Lee CF; Chen YA; Hernandez E; Pong RC; Ma S; Hofstad M; Kapur P; Zhau H; Chung LW; Lai CH; Lin H; Lee MS; Raj GV; Hsieh JT
    Clin Transl Med; 2022 Feb; 12(2):e695. PubMed ID: 35184376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAX6 promotes neuroendocrine phenotypes of prostate cancer via enhancing MET/STAT5A-mediated chromatin accessibility.
    Jing N; Du X; Liang Y; Tao Z; Bao S; Xiao H; Dong B; Gao WQ; Fang YX
    J Exp Clin Cancer Res; 2024 May; 43(1):144. PubMed ID: 38745318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
    Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D
    Nat Commun; 2020 Jan; 11(1):338. PubMed ID: 31953400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer.
    Lee JK; Bangayan NJ; Chai T; Smith BA; Pariva TE; Yun S; Vashisht A; Zhang Q; Park JW; Corey E; Huang J; Graeber TG; Wohlschlegel J; Witte ON
    Proc Natl Acad Sci U S A; 2018 May; 115(19):E4473-E4482. PubMed ID: 29686080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Models of Neuroendocrine Prostate Cancer.
    Cacciatore A; Albino D; Catapano CV; Carbone GM
    Curr Protoc; 2023 May; 3(5):e742. PubMed ID: 37166213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LIN28B promotes the development of neuroendocrine prostate cancer.
    Lovnicki J; Gan Y; Feng T; Li Y; Xie N; Ho CH; Lee AR; Chen X; Nappi L; Han B; Fazli L; Huang J; Gleave ME; Dong X
    J Clin Invest; 2020 Oct; 130(10):5338-5348. PubMed ID: 32634132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms underlying the development of neuroendocrine prostate cancer.
    Liu S; Alabi BR; Yin Q; Stoyanova T
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):57-68. PubMed ID: 35597438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.